|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||12.43 - 13.55|
|52 Week Range||4.72 - 18.50|
|Beta (5Y Monthly)||3.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1 diabetes (T1D) with two complementary disease state and screening education campaigns. "Connected by T1D" and "Type 1 Tested" are uniquely designed for healthcare professionals and patients and their relatives at increased risk of T1D, respectively, and aim to bring awareness to the importance and urgency of screening people with a family history of T1D for early-stage, pre-symptomatic disease.
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the submission of the clinical module of the Company's Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab (PRV-031), an investigational anti-CD3 monoclonal antibody for the delay or prevention of clinical Type 1 Diabetes (T1D) in at-risk individuals.